References
- Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–3428.
- Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488–496.
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–208.
- Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Haematologica 2014;99(Suppl. 1): Abstract 525.
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009. Available from: seer.cancer.gov
- Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319–2331.
- Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/ 8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25: 145–156.
- Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquistion of MYC: report of two cases and literature review. Int J Clin Exp Pathol 2013;6: 788–794.
- Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149–1159.
- Turakhia SK, Hill BT, Dufresne SD, et al. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. Am J Clin Pathol 2014; 142:339–346.
- Pan P, Debos L, Benito JM, et al. BCL-2 selective BH3 mimetic ABT-199 is a potent agent for acute myeloid leukemia. Blood 2013; 122(Suppl. 1): Abstract 1456.
- Th'ng KH, Garewal G, Kearney L, et al. Establishment and characterization of three new malignant lymphoid cell lines. Int J Cancer 1987;39:89–93.
- Chang H, Messner HA, Wang XH, et al. A human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest 1992;89:1014–1020.
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70: 440–446.
- Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. Methods Mol Biol 2011;731:421–434.
- Premkumar DR, Jane EP, Foster KA, et al. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 2013;346:201–210.
- Kita A, Nakahara T, Yamanaka K, et al. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011;35:787–792.
- Jane EP, Premkumar DR, DiDomenico JD, et al. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 2013;12:326–338.
- Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013;121: 2285–2288.
- Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular Subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6075.
- Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma Cancer 2012;118:3128–3134.
- Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904–917.
- Ott CJ, Kopp N, Bird L et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012;120:2843–2852.